Angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof

Abstract

The present invention provides a an angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof, wherein the complex comprises an angiotensin receptor antagonist and creatine phosphate sodium, a molar ratio of the angiotensin receptor antagonist to the creatine phosphate sodium is 1:1-2, and the angiotensin receptor antagonist is selected from valsartan, losartan, irbesartan, telmisartan, eprosartan, candesartan, olmesartan, saprisartan, tasosartan, and elisartan. According to the present invention, the complex is formed by compounding the angiotensin receptor antagonist and the creatine phosphate sodium, and provides the unexpected double effect and the synergistic effect for treatment of heart failure and high blood pressure, the cocrystallization salt hydrate formed by linking the hydrogen bond has the stable characteristic, the pharmacokinetic property is significantly provided, and the positive application prospects are provided in the fields of anti-high blood pressure treatment and anti-heart failure treatment.

Description

technical field [0001] The invention belongs to the field of drugs for treating diseases of the cardiovascular system, and particularly relates to a compound of angiotensin receptor antagonist and creatine sodium phosphate and its application. Background technique [0002] Heart failure (referred to as heart failure) is a complex clinical symptom group, which is a severe stage of various heart diseases. Its incidence rate is high, and its 5-year survival rate is similar to that of malignant tumors. The incidence of heart failure will continue to increase in the near future, and it is becoming the most important cardiovascular disease in the 21st century. [0003] According to foreign statistics, the prevalence of heart failure in the population is about 1.5E-2.0E, and it can reach 6%-10% over the age of 65. In the past 40 years, the death rate caused by heart failure has increased by 6 times. Heart failure is the initial myocardial injury due to any cause (such as myocardia...

AI Technical Summary

Problems solved by technology

[0008] However, currently there is no clinically effective drug for the simultaneous treatment of heart failure and hypertension, and most drugs have unavoidable side effects while relieving symptoms of heart failure and hypertension

And the single drug instruction is prone to tolerance. In order to treat heart failure and hypertension more effectively, some compounds have been developed in the prior art, such as the angiotensin II receptor for secondary prevention of myocardial infarction disclosed in CN1662256A. Combinations of somatoblockers and beta-blockers, the art discloses the use of valsartan and antihypertensive agents, which can be used to treat myocardial infarction and high blood pressure, but it is not disclosed that it can be used to treat heart failure at the same time and high blood pressure, and the compound disclosed in the technical scheme has no definite crystal structure, which can easily lead to unstable properties of the formed compound

Images